Research programme: anti-inflammatory monoclonal antibodies - Sorrento Therapeutics

Drug Profile

Research programme: anti-inflammatory monoclonal antibodies - Sorrento Therapeutics

Alternative Names: Anti-CGRP antibodies - Sorrento Therapeutics; Anti-PD-L1 antibodies - Sorrento Therapeutics; Anti-RAGE antibodies - Sorrento Therapeutics; STI B010X; STI-B120X; STI-B150X

Latest Information Update: 20 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sorrento Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Calcitonin gene-related peptide antagonists; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 01 May 2014 Preclinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top